HOME > BUSINESS
BUSINESS
- Otsuka Wants to Make Jnana Cornerstone of Future Drug Discovery: CEO
August 5, 2024
- Takeda Announces Reorganization, Buyout Program in Japan
August 5, 2024
- Daiichi Sankyo Kicks Off Global PIII Study for B7-H3-Directed ADC
August 5, 2024
- Takeda to Prune 1,000 Jobs in US
August 5, 2024
- Alecensa Nabs Additional Nod in Earlier NSCLC Setting: Chugai
August 5, 2024
- Eisai Stands Firmly Behind Leqembi Profile despite EU Rejection
August 5, 2024
- Kyowa Kirin Pulls Plug on Stand-Alone Sales in China, Retools Asian Strategy
August 2, 2024
- Otsuka Picks Up Jnana Therapeutics for US$800 Million
August 2, 2024
- Kyowa Kirin to Offer Buyout Packages amid Research Rejig
August 2, 2024
- Otsuka’s H1 Pharma Sales Soar 18% on Rexulti, Lonsurf
August 2, 2024
- Ono Inks Fresh GPCR Antibody Pact with Monash University
August 2, 2024
- Mitsubishi Tanabe’s Buyout Program Has No Bearing on Potential Divestment: EVP
August 2, 2024
- Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
August 2, 2024
- Leqembi’s April-June Sales Up 2.2-Fold from Prior Quarter: Eisai
August 2, 2024
- Maruho, Meiji to End Co-Promotion of Amenalief in Japan
August 2, 2024
- Toa Eiyo to Downsize Workforce by 100 through Voluntary Buyout
August 1, 2024
- Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
- SanBio’s Cell Therapy Akuugo Scores Conditional Approval
August 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Chugai to Develop Roche’s PI3K Inhibitor Inavolisib in Japan
August 1, 2024
ページ
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…